Published in Arch Intern Med on April 28, 2008
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause (2014) 1.50
Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology (2012) 1.27
Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol (2012) 1.10
Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging (2010) 1.00
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment. BMJ Open (2013) 0.89
Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women. Menopause (2012) 0.84
Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric (2012) 0.82
17β-estradiol and inflammation: implications for ischemic stroke. Aging Dis (2014) 0.81
Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke. Horm Behav (2012) 0.81
Hormone therapy and stroke: is it all about timing? Curr Treat Options Cardiovasc Med (2009) 0.77
Stroke: understanding the differences between males and females. Pflugers Arch (2013) 0.77
Iron, inflammation and atherosclerosis risk in men vs. perimenopausal women. Atherosclerosis (2015) 0.77
The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism (2016) 0.77
A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. Obstet Gynecol Int (2015) 0.76
Should hormone replacement therapy be used in postmenopausal women for voiding dysfunction? Can Urol Assoc J (2009) 0.75
Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study. Am J Public Health (2016) 0.75
Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen. Stroke (2016) 0.75
Sex differences in antiplatelet response in ischemic stroke. Womens Health (Lond Engl) (2011) 0.75
Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. Gastroenterology (2017) 0.75
Repeated Estradiol Treatment Attenuates Chronic Cerebral Hypoperfusion-Induced Neurodegeneration in Rat Hippocampus. Cell Mol Neurobiol (2015) 0.75
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Test of the National Death Index. Am J Epidemiol (1984) 8.46
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med (2000) 5.17
Cigarette smoking, relative weight, and menopause. Am J Epidemiol (1983) 4.46
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol (1987) 3.77
The National Survey of Stroke. Clinical findings. Stroke (1981) 3.45
Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) (2006) 2.77
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40
Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol (2004) 1.50
Determining the incidence of different subtypes of stroke: results from the Perth Community Stroke Study, 1989-1990. Med J Aust (1993) 1.17
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med (2008) 12.41
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr (2002) 6.96
Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr (2005) 6.67
Trans fatty acids and cardiovascular disease. N Engl J Med (2006) 6.67
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
A prospective study of sleep duration and mortality risk in women. Sleep (2004) 6.11
Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med (2003) 5.95
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67
Alternative dietary indices both strongly predict risk of chronic disease. J Nutr (2012) 5.60
Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study. Arch Intern Med (2005) 5.59
Obesity, weight gain, and the risk of kidney stones. JAMA (2005) 5.34
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med (2010) 5.05
Physical activity, including walking, and cognitive function in older women. JAMA (2004) 4.90
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med (2012) 4.72
Exercise type and intensity in relation to coronary heart disease in men. JAMA (2002) 4.69
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol (2014) 4.67
Merging and emerging cohorts: not worth the wait. Nature (2007) 4.66
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care (2002) 4.48
Habitual caffeine intake and the risk of hypertension in women. JAMA (2005) 4.46
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr (2004) 4.29
Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med (2004) 4.27
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24
Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med (2002) 4.21
Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med (2002) 4.19
Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med (2006) 4.16
Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA (2004) 4.04
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Association of nut consumption with total and cause-specific mortality. N Engl J Med (2013) 3.94
Diet and lifestyle risk factors associated with incident hypertension in women. JAMA (2009) 3.94
Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr (2009) 3.90
Estimating the number of deaths due to obesity: can the divergent findings be reconciled? J Womens Health (Larchmt) (2007) 3.86
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation (2005) 3.85
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 3.85
Effects of Initiating Moderate Alcohol Intake on Cardiometabolic Risk in Adults With Type 2 Diabetes: A 2-Year Randomized, Controlled Trial. Ann Intern Med (2015) 3.78
Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer (2007) 3.77
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA (2004) 3.69
Smoking and smoking cessation in relation to mortality in women. JAMA (2008) 3.68
Nut and peanut butter consumption and risk of type 2 diabetes in women. JAMA (2002) 3.68
Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med (2010) 3.66
Major dietary protein sources and risk of coronary heart disease in women. Circulation (2010) 3.65
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr (2004) 3.61
Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA (2002) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med (2003) 3.55
Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst (2003) 3.54
The expanding medical and behavioral resources with access to care for everyone health plan. Ann Intern Med (2009) 3.53
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation (2003) 3.50